All Posts

Putting ASX Healthcare in the Hot Seat in 2026

Dec 18, 2025

•

6 min read

Same Result. Two Markets. Very Different Answers.

Dec 17, 2025

•

9 min read

The Holiday Trade I like to do once a Year

Dec 16, 2025

•

7 min read

Trump floats new cannabis rules: Weeding out the good from the bad

Dec 15, 2025

•

11 min read

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Dec 12, 2025

•

9 min read

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Dec 11, 2025

•

9 min read

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Dec 10, 2025

•

9 min read

Immutep drops a US$370M deal... at 6:54pm

Dec 9, 2025

•

7 min read

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Dec 8, 2025

•

11 min read

Are AI-Predicted Clinical Trials the Future of Drug Development?

Dec 5, 2025

•

5 min read

The Moment Invion (IVX) Became “Investible” for me

Dec 4, 2025

•

7 min read

The Hidden Signals Found in AGM Updates

Dec 3, 2025

•

7 min read

1...10 11 12 13

All Posts

Putting ASX Healthcare in the Hot Seat in 2026

Same Result. Two Markets. Very Different Answers.

The Holiday Trade I like to do once a Year

Trump floats new cannabis rules: Weeding out the good from the bad

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Immutep drops a US$370M deal... at 6:54pm

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Are AI-Predicted Clinical Trials the Future of Drug Development?

The Moment Invion (IVX) Became “Investible” for me

The Hidden Signals Found in AGM Updates

The Armchair Analyst